Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Single most important change
View:
Post by DJDawg on Aug 29, 2022 10:52pm

Single most important change

The biggest change that I can see is the way the 360 patient CR has gone up
Because it seems from previous data that all patients who make it to 360 CR keep it at 450. Recall that the previous 360 was 5 patients, followed by 5 at 450.

Now we have 9 patients at 360 (35% of 26) there is quite a good chance that those 4 new CR patients will flow into 450 day totals. Those will bump up the 450 day percent quite nicely.

Other comments:
- the last few days we have witnessed a lot of swings. Whether from nervous people thinking that the numbers are not going to support the stock or from people playing the swing trade game. Since all those people follow the stock, my prediction is that many will try to swing back in. Since the longholders are not selling, I wonder if there will be a rally.
- Dr. Vera leaving is interesting and confusing. The thing that keeps me grounded is that the data all has to go through the lead medical investigators. The data cannot be manipulated by someone at TLT. Given the science behind Dr. Macfarland's work and the amazing phase 1 b patients (1 and done cure in two patient) I know that there is no shadyness behind the science. Having read reviews by people who worked at the company it doesn't sound that fun to work there. Just what is there in other forums. I do think it is possible that the work environment for TLT is not great.

All in all I continue to have great confidence in the science and middling confidence in the company itself. I think the science will get us to to the finish line no matter how many time wasting/money wasting lawsuits are launched.
Comment by CancerSlayer on Aug 30, 2022 1:11am
As reported in the 5/30/2022 MD&A for 360 day data: 5 of 23 evaluable patients were CR (22%)...2 patients from Ph1b  4 of 23 evaluable patients were PR (17%) Today's report: 9 of 26 evaluable patients were CR (35%)...2 patients from Ph1b 3 of 26 evaluable patients were PR (12%) As of today, there are 4 additional 360 day CR patients & an increase in 3 total evaluable ...more  
Comment by CancerSlayer on Aug 30, 2022 1:17am
  Grammatically correct wording....an increase "of" 3 total evaluable patients.... : )
Comment by Oilminerdeluxe on Aug 30, 2022 1:32am
The 360 bump was nice to see. Should be good odds of seeing a great 450 day increase too next update. Crickets when it comes to share price as usual today? Hope TLT can churn up its value but perhaps that will only happen if BTD and AA is approved. Thanks all for the comments and number crunching. Helps out a lot.
Comment by CancerSlayer on Aug 30, 2022 2:15am
  Upon further review of the May 30 data reported...            360 day         450 day CR          5                   5 PR          4                   2 NR        14 ...more  
Comment by Eoganacht on Aug 30, 2022 2:16am
Nice. The 3 additional patients evaluated at 360 days were all CR plus we get one more CR from a previously PR patient. There were 6 more patients evaluated at 270 days. 4 of the 6 were CR and 2 of them were PR. (There were also 3 more patients classified as PR - I'm guessing 3 patients went from NR to PR!) All of the 6 more 270 day evaluees could end up being categorized as CR.
Comment by Lesalpes29 on Aug 30, 2022 6:21am
Amen! Very good post. Thank you.
Comment by skier59 on Aug 30, 2022 8:46am
Hum YA !!!!!.....
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250